CKc-funded Indoximod Research Published
Dr. Theodore Johnson received the first grant CKc ever awarded. In the nearly 10 years since that first investment, CKc has funded Dr. Johnson multiple times and Dr. Johnson has gone on to receives millions of dollars from many foundations to bring this research to fruition. The reason for our initial investment in Dr. Johnson was because he was not only interested in lengthening the lives of kids fighting the deadliest cancers, but his aim was to provide them with quality of life for the time they had remaining with their families. Dr. Johnson’s vision is a testament to the kind of physician he is: warm, compassionate, hopeful.
We are proud to share this published article on the research that CKc donors helped make possible. Dr. Johnson’s research is giving families more time, a precious commodity in the world of pediatric cancer. He is helping these families create priceless memories, and CKc donors make that possible.
The authors’ manuscript is available online now at this link: https://doi.org/10.1093/
Citation:
Theodore S Johnson, Tobey J MacDonald, Rafal Pacholczyk, Dolly Aguilera, Ahmad Al-Basheer, Manish Bajaj, Pratiti Bandopadhayay, Zuzana Berrong, Eric Bouffet, Robert C Castellino, Kathleen Dorris, Bree R Eaton, Natia Esiashvili, Jason R Fangusaro, Nicholas Foreman, Diana Fridlyand, Cole Giller, Ian M Heger, Chenbin Huang, Nadja Kadom, Eugene P Kennedy, Neevika Manoharan, William Martin, Colleen McDonough, Rebecca S Parker, Vijay Ramaswamy, Eric Ring, Amyn Rojiani, Ramses F Sadek, Sarthak Satpathy, Matthew Schniederjan, Amy Smith, Christopher Smith, Beena E Thomas, Rachel Vaizer, Kee Kiat Yeo, Manoj K Bhasin, David H Munn, Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial, Neuro-Oncology 2023. DOI: 10.1093/neuonc/noad174.
